Lovaza

Lovaza is a brand name of omega-3 polyunsaturated fatty acids, approved by the FDA in the following formulation(s):

LOVAZA (omega-3-acid ethyl esters - capsule; oral)

• 
  Manufacturer: SMITHKLINE BEECHAM
  
  Approval date: November 10, 2004
  
  Strength(s): 1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS ^[RLD]

Has a generic version of Lovaza been approved?

No. There is currently no therapeutically equivalent version of Lovaza available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Lovaza. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Fatty acid composition
  Patent 5,502,077
  Issued: March 26, 1996
  Inventor(s): Breivik; Harald & Borretzen; Bernt & Dahl; Knut H. & Krokan; Hans E. & Bonaa; Kaare H.
  Assignee(s): Norsk Hydro A.S.
  Fatty acid composition comprising at least 80% by weight of omega-3-fatty acids, salts or derivatives thereof, wherein (all-Z)-5,8,11,14,17-eicosapentaenoic acid (EPA) and (all-Z)-4,7,10,13,16,19-docosahexaenoic acid comprises at least 75% by weight of the total fatty acids. The compositions can be used for the treatment or prophylaxis of multiple risk factors for cardiovascular diseases.
  
  Patent expiration dates:
  
  
  • March 26, 2013
    
    ✓ 
    Patent use: USE IN LIPID MANAGEMENT
    ✓ 
    Drug substance
  
  



• 
  Fatty acid composition
  Patent 5,656,667
  Issued: August 12, 1997
  Inventor(s): Breivik; Harald & B.o slashed.rretzen; Bernt & Dahl; Knut Helk.ang.s & Krokan; Hans Einar & B.o slashed.naa; Kaare Harald
  Assignee(s): Norsk Hydro as
  Fatty acid composition comprising at least 80% by weight of omega-3-fatty acids, salts or derivatives thereof, wherein (all-Z)-5,8,11,14,17-eicosapentaenoic acid (EPA) and (all-Z)-4,7,10,13,16,19-docosahexaenoic acid comprises at least 75% by weight of the total fatty acids. The compositions can be used for the treatment or prophylaxis of multiple risk factors for cardiovascular diseases.
  
  Patent expiration dates:
  
  
  • April 10, 2017
    
    ✓ 
    Patent use: USE IN LIPID MANAGEMENT
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Pharmaceutical composition comprising low concentrations of environmental pollutants
  Patent 7,732,488
  Issued: June 8, 2010
  Inventor(s): Breivik; Harald & Thorstad; Olav
  Assignee(s): Pronova Biopharma Norge AS
  The invention relates to a process for decreasing the amount of environmental pollutants in a mixture comprising a fat or an oil, being edible or for use in cosmetics, the fat or oil containing the environmental pollutants, which process comprises the steps of adding a volatile working fluid to the mixture, where the volatile working fluid comprises at least one of a fatty acid ester, a fatty acid amide, a free fatty acid and a hydro-carbon, and subjecting the mixture with the added volatile working fluid to at least one stripping processing step, in which an amount of environmental pollutant present in the fat or oil, being edible or for use in cosmetics, is separated from the mixture together with the volatile working fluid. The present invention also relates to a volatile environmental pollutants decreasing working fluid, for use in decreasing an amount of environmental pollutants present in a fat or oil, being edible or for use in cosmetics. In addition, the present invention relates to a health supplement, a pharmaceutical and an animal feed product prepared according to the process mentioned above.
  
  Patent expiration dates:
  
  
  • January 30, 2025
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • September 16, 2012 - INCLUSION OF RESULTS FROM TWO DRUG INTERACTION STUDIES WITH LIPITOR AND CRESTOR IN CLINICAL PHARMACOLOGY SECTION
  
  

See also...

• Lovaza Consumer Information (Wolters Kluwer)
• Lovaza Consumer Information (Cerner Multum)
• Lovaza Advanced Consumer Information (Micromedex)
• Folic Acid/Vitamin B6/Vitamin B12/Omega-3 Acids/Phytosterols Consumer Information (Wolters Kluwer)
• Folic Acid/Vitamin B6/Vitamin B12/Omega-3 Fatty Acids/Biotin/Chromium Consumer Information (Wolters Kluwer)
• Omega-3-Acid Ethyl Esters Consumer Information (Wolters Kluwer)
• Omega-3 polyunsaturated fatty acids Consumer Information (Cerner Multum)
• Omega-3-acid ethyl esters Advanced Consumer Information (Micromedex)
• Omega-3-acid Ethyl Esters AHFS DI Monographs (ASHP)
• Fish Oils Natural Product Information (Facts & Comparisons)